Premium
Emergence of Antinuclear Antibodies in Psoriatic Patients Treated with Infliximab: Personal Experience and Literature Review
Author(s) -
Chimenti Maria Sole,
Spinelli Francesca Romana,
Giunta Alessandro,
Martinelli Francesco,
Saraceno Rosita,
Conti Fabrizio,
Perricone Roberto,
Valesini Guido
Publication year - 2014
Publication title -
drug development research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.582
H-Index - 60
eISSN - 1098-2299
pISSN - 0272-4391
DOI - 10.1002/ddr.21198
Subject(s) - infliximab , psoriasis , medicine , anti nuclear antibody , psoriatic arthritis , tumor necrosis factor alpha , etanercept , incidence (geometry) , dermatology , immunology , pathogenesis , antibody , population , gastroenterology , autoantibody , physics , optics , environmental health
Postmarketing Phase IVPsoriasis is a chronic inflammatory skin disease affecting up to 2.5% of the population, with joint involvement in approximately 30% of patients. Given the role of tumor necrosis factor ( TNF ) in the pathogenesis of psoriasis, anti‐ TNF therapies have been developed; several studies have demonstrated the efficacy of infliximab ( IFX ) as induction and maintenance therapy in the treatment of moderate to severe plaque psoriasis. The development of antinuclear antibodies ( ANA ) in anti‐ TNF ‐treated patients has been frequently reported. The aim of this study was to investigate the incidence of ANA and anti‐double stranded DNA (anti‐ds DNA ) antibodies in psoriatic patients receiving IFX . Incidence of new ANA and anti‐ds‐ DNA was 16.2% and 8.1% respectively. No case of anti‐ TNF induced L upus was observed during the follow‐up.